PERK: A novel therapeutic target for neurodegenerative diseases?

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Ma, Tao ^a   Klann, Eric ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 2606414; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DEGENERATIVE DISEASE; DRUG TARGETING; ENDOPLASMIC RETICULUM; MOUSE; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRION DISEASE; PRIORITY JOURNAL; STRESS;

EID: 84901803359     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt260     Document Type: Article

References (15)

1. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. JA Moreno, M Halliday, C Molloy, H Radford, N Verity, JM Axten, CA Ortori, AE Willis, PM Fischer, DA Barrett, GR Mallucci, Sci Transl Med 2013 5 206ra138 24107777
2. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3- dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). JM Axten, JR Medina, Y Feng, A Shu, SP Romeril, SW Grant, WH Li, DA Heerding, E Minthorn, T Mencken, C Atkins, Q Liu, S Rabindran, R Kumar, X Hong, A Goetz, T Stanley, JD Taylor, SD Sigethy, GH Tomberlin, AM Hassell, KM Kahler, LM Shewchuk, RT Gampe, J Med Chem 2012 55 7193 7207 10.1021/jm300713s 22827572
3. Translational control and the unfolded protein response. RC Wek, DR Cavener, Antioxid Redox Signal 2007 9 2357 2371 10.1089/ars.2007.1764 17760508 (Pubitemid 350064140)
4. Translational control by eIF2 kinases in long-lasting synaptic plasticity and long-term memory. MA Trinh, E Klann, Neurobiol Learn Mem 2013 105 93 99 23707798
5. Coping with stress: eIF2 kinases and translational control. RC Wek, H-Y Jiang, TG Anthony, Biochem Soc Trans 2006 34 7 11 10.1042/BST0340007 16246168 (Pubitemid 43235522)
6. Shut-down of translation, a global neuronal stress response: mechanisms and pathological relevance. W Paschen, CG Proud, G Mies, Curr Pharm Des 2007 13 1887 1902 10.2174/138161207780858401 17584115 (Pubitemid 47017993)
7. Translational control of synaptic plasticity and learning and memory. E Klann, JD Richter, Translational Control in Biology and Medicine Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, Mathews MB, Sonenberg N, Hershey JW, 2007 485 506
8. The role of protein synthesis during the labile phases of memory: revisiting the skepticism. C Alberini, Neurobiol Learn Mem 2008 89 234 246 10.1016/j.nlm.2007.08.007 17928243 (Pubitemid 351318267)
9. Endoplasmic reticulum dysfunction in neurological disease. BD Roussel, AJ Kruppa, E Miranda, DC Crowther, DA Lomas, SJ Marciniak, Lancet Neurol 2013 12 105 118 10.1016/S1474-4422(12)70238-7 23237905
10. Suppression of eIF2 kinases alleviates Alzheimer's disease-related plasticity and memory deficits. T Ma, MA Trinh, AJ Wexler, C Bourbon, E Gatti, P Pierre, DR Cavener, E Klann, Nat Neurosci 2013 16 1299 1305 10.1038/nn.3486 23933749
11. Brain-specific disruption of the eIF2 kinase PERK decreases ATF4 expression and impairs behavioral flexibility. MA Trinh, H Kaphzan, RC Wek, P Pierre, DR Cavener, E Klann, Cell Rep 2012 1 676 688 10.1016/j.celrep.2012.04. 010 22813743
12. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. P Zhang, B McGrath, S Li, A Frank, F Zambito, J Reinert, M Gannon, K Ma, K McNaughton, DR Cavener, Mol Cell Biol 2002 22 3864 3874 10.1128/MCB.22.11.3864-3874.2002 11997520 (Pubitemid 34525227)
13. Wolcott-Rallison syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. V Senée, KM Vattem, M Delépine, LA Rainbow, C Haton, A Lecoq, NJ Shaw, JJ Robert, R Rooman, C Diatloff-Zito, JL Michaud, B Bin-Abbas, D Taha, B Zabel, P Franceschini, AK Topaloglu, GM Lathrop, TG Barrett, M Nicolino, RC Wek, C Julier, Diabetes 2004 53 1876 1883 10.2337/diabetes.53.7.1876 15220213 (Pubitemid 38857047)
14. Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. D Galasko, TE Golde, Alzheimers Res Ther 2013 5 10 10.1186/alzrt164 23470193
15. Open questions for Alzheimer's disease immunotherapy. TE Golde, Alzheimers Res Ther 2014 6 3 10.1186/alzrt233 24393284